港股異動 | 上海醫藥AH股齊漲 H股升8%創3個半月新高
格隆匯11月2日丨上海醫藥H股現漲8%,報12.18港元創3個半月新高價,A股漲7.7%,報19.28元。近日,公司阿奇黴素片及鹽酸特拉唑嗪片通過仿製藥一致性評價。另外,招證國際維持上海醫藥H股“增持”評級,指其三季度收入端復甦,該行維持公司22/23年的財務預測不變。此外,上藥康希諾目前擁有2億劑/年的疫苗產能,可用於新型吸入用重組新冠疫苗的生產。該行認為公司通過此項業務有望強化其疫苗領域佈局,並獲得更多創新疫苗產品的進口總代理資格。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.